Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

This trial tests a combination of two targeted drugs — binimetinib and encorafenib — for melanoma that has spread to the brain. These drugs target a specific mutation (BRAF V600) that drives tumor growth. The study includes both patients who have already tried BRAF-targeted drugs and those who haven't. **You may be eligible if...** - You are 18 or older - You have melanoma confirmed to have a BRAF V600 mutation - Your cancer has spread to the brain (including fluid around the brain in some cases) - Cohort A: You have already been treated with BRAF inhibitors and your brain metastases are progressing - Cohort B: You have not yet received BRAF/MEK inhibitor treatment **You may NOT be eligible if...** - You do not have the BRAF V600 mutation in your tumor - Your brain metastases are too large or too numerous for this protocol - Your overall health is too poor to tolerate the treatment Talk to your doctor to see if this trial is right for you.